Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Huntington Ingalls Industries Inc (HII) Price & Performance

Enveric Biosciences IncTrade
Huntington Ingalls Industries IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Huntington Ingalls Industries Inc — how do they compare? Enveric Biosciences Inc trades at $1.59 (market cap $6.20M), while Huntington Ingalls Industries Inc trades at $329.05 (market cap $12.92B). The key difference: Huntington Ingalls Industries Inc is far larger — about 2083.9× Enveric Biosciences Inc's market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBHII
Market Cap
$6.20M$12.92B
Sector
HealthTechnology
52-Week High
$17.40$453.73
52-Week Low
$1.27$265.40
Enterprise Value
$1.30M$15.84B
Dividend Yield
1.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.59, up 3.25% today, with a bullish technical signal driven by moving averages. The company, a biotechnology firm developing neuroplastogenic therapeutics, reported significant earnings beats in all quarters of 2025, including a positive EPS of $0.85 in Q4 versus an expected loss. Recent news highlights progress with its lead candidate EB-003, including non-hallucinogenic profile confirmations and FDA guidance alignment, though financials show negative ROE and ROA with net income of -$8.77M in 2025.

The outlook is cautiously optimistic due to strong analyst support (75% buy ratings) and clinical advancements, but high financial losses and reliance on financing cash flow pose risks. Stock performance hinges on successful drug development milestones and future profitability, with current sentiment buoyed by technical strength and positive pipeline updates.

Huntington Ingalls Industries Inc

HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII